Last: | $12.79 |
---|---|
Change Percent: | -1.43% |
Open: | $12.8 |
Close: | $12.79 |
High: | $12.8 |
Low: | $12.775 |
Volume: | 1,758 |
Last Trade Date Time: | 07/24/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$12.79 | $12.8 | $12.79 | $12.8 | $12.775 | 1,758 | 07-24-2024 |
$12.62 | $12.45 | $12.62 | $12.75 | $12.4 | 6,725 | 07-23-2024 |
$12.8 | $12.66 | $12.8 | $12.8 | $12.425 | 2,580 | 07-22-2024 |
$12.65 | $12.31 | $12.65 | $12.65 | $12.3 | 4,019 | 07-19-2024 |
$12.62 | $12.93 | $12.62 | $12.93 | $12.36 | 9,191 | 07-18-2024 |
$13 | $13.04 | $13 | $13.25 | $12.61 | 38,645 | 07-17-2024 |
$13.23 | $13.53 | $13.23 | $13.6499 | $12.6 | 25,980 | 07-16-2024 |
$13.51 | $13 | $13.51 | $13.9499 | $13 | 93,127 | 07-15-2024 |
$12.72 | $12.14 | $12.72 | $13.24 | $12 | 462,018 | 07-12-2024 |
$9.7 | $9.82 | $9.7 | $10.01 | $9.7 | 6,007 | 07-11-2024 |
$10.01 | $10.1588 | $10.01 | $10.1588 | $10.01 | 5,482 | 07-10-2024 |
$10.0101 | $10.15 | $10.0101 | $10.15 | $10.0101 | 858 | 07-09-2024 |
$10.1599 | $10.16 | $10.1599 | $10.16 | $10.0531 | 2,949 | 07-08-2024 |
$9.89 | $10.04 | $9.89 | $10.17 | $9.6201 | 5,625 | 07-05-2024 |
$10.2199 | $10.05 | $10.2199 | $10.295 | $10 | 3,214 | 07-04-2024 |
$10.2199 | $10.05 | $10.2199 | $10.295 | $10 | 3,214 | 07-03-2024 |
$10.04 | $10.76 | $10.04 | $10.76 | $10.04 | 3,205 | 07-02-2024 |
$10.3 | $10.21 | $10.3 | $10.505 | $10.21 | 6,404 | 07-01-2024 |
$10.29 | $10 | $10.29 | $10.56 | $10 | 2,697 | 06-28-2024 |
$9.91 | $9.76 | $9.91 | $10.8 | $9.72 | 44,117 | 06-27-2024 |
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.2493 on volume of 118,503,418 shares Qualigen Therapeutics Inc. (QLGN) rose 94.8% to $0.4 on volume of 100,863,101 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 20.0% to $0.098...
DALLAS, May 10, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its first quarter 2024 financial results and provided a corporate update. Recent...